Skip to main content
    A

    Adaptive Biotechnologies Corp (ADPT)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $28.49
    +0.62 (+2.22%)

    Market Cap: $4.70B

    Last updated: Nov 17, 2026 at 4:33 PM ET

    Adaptive Biotechnologies Corp (ADPT) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Adaptive Biotechnologies (ADPT) has a market cap of $4.70B and an enterprise value of $4.63B. Its share count is up 5.23% from a year earlier. It kept -23.73% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 1.61% below the market cap, as cash exceeds debt.

    Market Cap$4.70B
    Enterprise Value$4.63B
    Latest price (Nov 17, 2026)$28.49

    Key Dates

    The next earnings report is expected on Feb 3, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 3, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.34% in the quarter ended Sep 30, 2026 and grew 4.28% a year over 2 years.

    Shares Outstanding160.40M
    Shares Change (YoY)+5.23%
    Shares Change (QoQ)+0.34%
    Share Count Growth (2Y CAGR)+4.28%

    Valuation Ratios

    Sales and book value multiples are 15.3x and 25.9x. Its year-end P/S ranged from 4.2x to 81.5x from 2019 to 2025.

    P/S Ratio15.3x
    Forward P/S15.3x
    P/B Ratio25.9x
    P/TBV Ratio80.5x

    Valuation history and multiples

    Price Statistics

    The stock is up 102.06% over 52 weeks and trades 5.28% above its 50-day average.

    Beta (1Y)1.53
    52-Week Change+102.06%
    1-Month Change+18.96%
    3-Month Change+11.77%
    6-Month Change+119.83%
    5-Year Change-20.26%
    Total Return (1Y)+102.06%
    Total Return (3Y CAGR)+87.65%
    Total Return (5Y CAGR)-0.08%
    Return vs SPY (1Y)+95.64%
    Max Drawdown (1Y)-39.35%
    Max Drawdown (3Y)-56.19%
    Sharpe Ratio (1Y)1.10
    Correlation with SPY (1Y)0.32
    50-Day Average$27.06
    200-Day Average$20.19
    52-Week Range$12.00 to $32.21
    RSI (14 Days)54.4
    Average Volume (20 Days)2.31M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.97x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio3.97x
    Quick Ratio3.87x
    Debt / Equity0.00x
    Interest Coverage-1.47x

    Returns and Efficiency

    Return on equity is -40.14% over the last 12 months, against a 5-year average of -51.29%.

    Return on Equity (ROE)-40.14%
    Return on Assets (ROA)-10.35%
    Return on Capital Employed (ROCE)-8.25%
    ROE (5Y Average)-51.29%
    ROA (5Y Average)-24.22%
    ROIC (5Y Average)-28.37%
    Asset Turnover0.51x
    Inventory Turnover7.50x
    Receivables Turnover5.13x
    Cash Conversion Cycle92 days

    Scores

    ADPT has an Altman Z-Score of 3.30, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.

    Altman Z-Score3.30
    Altman Z ZoneSafe
    Piotroski F-Score5 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $298.01M over the last 12 months is up 17.91% from the 12 months before.

    Revenue$298.01M
    Revenue Growth (YoY)+17.91%
    Gross Profit$220.98M
    Operating Income-$48.21M
    Pretax Income-$70.73M
    Net Income-$70.73M
    EBITDA-$34.05M
    EBIT-$48.21M
    Reported EPS (TTM)-$0.30

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 25.79% of the $683.12M in total assets.

    Cash and Equivalents$75.61M
    Total Debt$0
    Net Cash$75.61M
    Net Cash Per Share$0.47
    Working Capital$293.72M
    Shareholder Equity$176.21M
    Book Value Per Share$1.10
    Tangible Book Value$56.78M
    Tangible Book Per Share$0.35
    Total Assets$683.12M
    Total Liabilities$499.23M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $4.54M of capital spending, operating cash flow left -$8.82M of free cash flow.

    Operating Cash Flow-$4.28M
    Capital Expenditures$4.54M
    Free Cash Flow-$8.82M
    FCF Per Share-$0.06
    Depreciation and Amortization$14.59M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -16.18%, against a 5-year average of -97.64%.

    Gross Margin74.15%
    Operating Margin-16.18%
    Pretax Margin-23.73%
    Net Margin-23.73%
    EBITDA Margin-11.43%
    EBIT Margin-16.18%
    FCF Margin-2.96%
    Gross Margin (5Y Average)65.28%
    Operating Margin (5Y Average)-97.64%
    Net Margin (5Y Average)-97.08%

    Growth

    Revenue grew 14.34% a year over 3 years.

    Revenue Growth (3Y CAGR)+14.34%
    Revenue Growth (5Y CAGR)+23.00%
    Book Value Per Share Growth (2Y CAGR)-18.07%
    Tangible Book Per Share Growth (2Y CAGR)-29.03%

    Revenue and profit by year

    Dividends and Yields

    ADPT does not pay a dividend. Its free cash flow yield is -0.19%.

    FCF Yield-0.19%
    Shareholder Yield0.00%

    Peer Position

    Against 12 similar companies, ADPT has the 3rd highest P/S.

    P/S Ratio15.3x vs 3.9x median
    Revenue Growth (Trailing 4 Quarters, YoY)+17.91% vs +13.98% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 16.10% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+16.10%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About ADPT

    What is ADPT's market cap?

    Adaptive Biotechnologies has a market cap of $4.70B. Its enterprise value, which adds debt and subtracts cash, is $4.63B.

    How many shares of ADPT are outstanding?

    Adaptive Biotechnologies has 160.40M shares outstanding. The count is up 5.23% from a year earlier.

    Does ADPT pay a dividend?

    No. Adaptive Biotechnologies does not pay a dividend.

    How much debt does ADPT have?

    Adaptive Biotechnologies has $0 of total debt and $75.61M of cash and equivalents, a net cash position of $75.61M.